83 related articles for article (PubMed ID: 19353622)
21. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
22. Central nervous system relapse in acute promyelocytic leukaemia.
Lunghi M; Castagnola C; Calatroni S; Bernasconi P; Lazzarino M
Haematologica; 2006 Jun; 91(6 Suppl):ECR24. PubMed ID: 16785127
[No Abstract] [Full Text] [Related]
23. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
[TBL] [Abstract][Full Text] [Related]
24. Late relapse of acute promyelocytic leukemia in a patient with no maintenance therapy.
Zhan H; Rajasree R; Russo L; Patel D
Am J Hematol; 2007 Mar; 82(3):248. PubMed ID: 16955464
[No Abstract] [Full Text] [Related]
25. Differentiation therapy in acute promyelocytic leukemia: European experience.
Degos L
J Cell Physiol; 1997 Nov; 173(2):285-7. PubMed ID: 9365538
[TBL] [Abstract][Full Text] [Related]
26. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
27. Reduced intensity conditioning allogeneic bone marrow transplantation following central nervous system (CNS) relapse of acute promyelocytic leukemia: evidence for a graft-versus-leukemia effect in the CNS.
Ostronoff M; Domingues MC; Ostronoff F; Matias C; Florêncio R; Matias K; Souto Maior AP; Sucupira A; Calixto R; Tagliari C
Am J Hematol; 2006 May; 81(5):387-8. PubMed ID: 16628719
[No Abstract] [Full Text] [Related]
28. Acute myeloid leukaemia and retinoids.
Norum KR
Eur J Clin Nutr; 1993 Feb; 47(2):77-87. PubMed ID: 8436093
[No Abstract] [Full Text] [Related]
29. Development and overcoming of ATRA resistance in acute promyelocytic leukemia.
Lo Coco F
Haematologica; 1999 Nov; 84(11):961-2. PubMed ID: 10553153
[No Abstract] [Full Text] [Related]
30. [Liposomal daunorubicin (daunosom) in the treatment of recurrent acute promyelocytic leukemia].
Pivnik AV; Shtroiakovskiĭ DL; Medvedev PV; Moiseeva TN; Shklovskiĭ-Kordi NE; Skorokhod AA
Ter Arkh; 1999; 71(7):24-7. PubMed ID: 10481863
[No Abstract] [Full Text] [Related]
31. Acute promyelocytic leukemia: from treatment to genetics and back.
Kogan SC; Bishop JM
Oncogene; 1999 Sep; 18(38):5261-7. PubMed ID: 10498878
[No Abstract] [Full Text] [Related]
32. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?
Grimwade D; Tallman MS
Leuk Res; 2011 Jan; 35(1):3-7. PubMed ID: 20674017
[No Abstract] [Full Text] [Related]
33. Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia.
Ammatuna E; Cavaliere A; Divona M; Amadori S; Scambia G; Lo-Coco F
Br J Haematol; 2009 Aug; 146(3):341. PubMed ID: 19545283
[No Abstract] [Full Text] [Related]
34. Concurrent craniospinal radiotherapy and intrathecal chemotherapy in patient with acute promyelocytic leukemia second relapsed in central nervous system (CNS) following allogeneic stem cell transplantation.
Lee HY; Kim KM; Kang MH; Kang JH; Kang KM; Lee GW
J Neurooncol; 2006 Aug; 79(1):73-5. PubMed ID: 16718520
[No Abstract] [Full Text] [Related]
35. Pharmacokinetics of all-trans retinoic acid in adults and children with acute promyelocytic leukemia.
Takitani K; Koh M; Inoue A; Kawakami C; Kuno T; Tamai H
Am J Hematol; 2006 Sep; 81(9):720-1. PubMed ID: 16838336
[No Abstract] [Full Text] [Related]
36. Central nervous system relapse in acute promyelocytic leukaemia treated with ATRA.
Currie J; Chee YL; Culligan DJ
Br J Haematol; 1997 Nov; 99(2):469. PubMed ID: 9375778
[No Abstract] [Full Text] [Related]
37. [The treatment of acute promyelocytic leukemia with retinoic acid].
Iavorkovskiĭ LI; Udris OIu; Iavorkovskiĭ LL
Ter Arkh; 1994; 66(2):87-9. PubMed ID: 8160157
[No Abstract] [Full Text] [Related]
38. Tumor treating fields therapy for recurrent glioblastoma.
Manag Care; 2012 Dec; 21(12):43-4. PubMed ID: 23304737
[No Abstract] [Full Text] [Related]
39. The expanding role of arsenic in acute promyelocytic leukemia.
Tallman MS
Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
[TBL] [Abstract][Full Text] [Related]
40. Searching the central nervous system for relapsed acute promyelocytic leukemia.
Stein EM; Tallman MS
Leuk Lymphoma; 2013 Dec; 54(12):2584-5. PubMed ID: 23662989
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
